SLC5A2 and type 2 diabetes mellitus: In EMPA-HEART CardioLink-6 [5] and DAPA-LVH (Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes) [14], SGLT2 inhibition led to LV mass regression in patients with T2DM and CAD or T2DM and LV hypertrophy, respectively.